2.1.1.1

stable recombinant expression of enzyme NNMT in the SH-SY5Y human neuroblastoma cell line, which has no endogenous enzyme expression, at levels of activity comparable with that in Parkinson's disease brain, recombinant expression of enzyme NNMT in SH-SY5Y human neuroblastoma and N27 rat mesencephalic dopaminergic neurones increases neurite branching, synaptophysin expression and dopamine accumulation and release. Recombinant NNMT-V5 expression in SH-SY5Y cells changes cellular morphology and increases dopamine uptake and release. Transient expression of enzyme NNMT in N27 cells

Homo sapiens

2.1.1.1

enzyme expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signalling

Homo sapiens

2.1.1.1

S-adenosyl-L-methionine + nicotinamide

Homo sapiens

S-adenosyl-L-homocysteine + 1-methylnicotinamide

?

2.1.1.1

Homo sapiens

2.1.1.1

no activity in the SH-SY5Y human neuroblastoma cell line and in N27 cells

Homo sapiens

2.1.1.1

neuron

Homo sapiens

2.1.1.1

S-adenosyl-L-methionine + nicotinamide

733625

Homo sapiens

S-adenosyl-L-homocysteine + 1-methylnicotinamide

?

2.1.1.1

S-adenosyl-L-methionine

Homo sapiens

2.1.1.1

stable recombinant expression of enzyme NNMT in the SH-SY5Y human neuroblastoma cell line, which has no endogenous enzyme expression, at levels of activity comparable with that in Parkinson's disease brain, recombinant expression of enzyme NNMT in SH-SY5Y human neuroblastoma and N27 rat mesencephalic dopaminergic neurones increases neurite branching, synaptophysin expression and dopamine accumulation and release. Recombinant NNMT-V5 expression in SH-SY5Y cells changes cellular morphology and increases dopamine uptake and release. Transient expression of enzyme NNMT in N27 cells

Homo sapiens

2.1.1.1

S-adenosyl-L-methionine

Homo sapiens

2.1.1.1

enzyme expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signalling

Homo sapiens

2.1.1.1

S-adenosyl-L-methionine + nicotinamide

Homo sapiens

S-adenosyl-L-homocysteine + 1-methylnicotinamide

?

2.1.1.1

no activity in the SH-SY5Y human neuroblastoma cell line and in N27 cells

Homo sapiens

2.1.1.1

neuron

Homo sapiens

2.1.1.1

S-adenosyl-L-methionine + nicotinamide

733625

Homo sapiens

S-adenosyl-L-homocysteine + 1-methylnicotinamide

?

2.1.1.1

malfunction

the enzyme effects on neurons are reduced in cells lacking epinephrin EFNB2 or Akt

Homo sapiens

2.1.1.1

metabolism

the effects of enzyme NNMT expression in SH-SY5Y cells, e.g. protection against the toxicity of the Complex I (CxI) inhibitors 1-methyl-4-phenylpyridinium ion and rotenone, are mediated via increased CxI activity and ATP production and the sequential activation of the epinephrin EFNB2 and Akt signalling pathways

Homo sapiens

2.1.1.1

physiological function

the enzyme NNMT expression protects against neurotoxin-mediated cell death by increasing Complex I (CxI) activity, resulting in increased ATP synthesis, mediated via protection of the NDUFS3 subunit of CxI from degradation by increased 1-methylnicotinamide production. The enzyme expression increases neurite branching and the presynaptic marker synaptophysin, synaptophysin expression is induced by the enzyme. 1-Methylnicotinamide replicates the effects of enzyme NNMT expression upon SH-SY5Y neurite branching, effects of NNMT expression on neuron morphology and differentiation, overview. Recombinant NNMT-V5 expression in SH-SY5Y cells changes cellular morphology and increases dopamine uptake and release. The effects of enzyme NNMT expression in SH-SY5Y cells, e.g. protection against the toxicity of the Complex I (CxI) inhibitors 1-methyl-4-phenylpyridinium ion and rotenone, are mediated via increased CxI activity and ATP production and the sequential activation of the epinephrin EFNB2 and Akt signalling pathways. The enzyme NNMT reduces cholinergic phenotype but does not induce terminal differentiation

Homo sapiens

2.1.1.1

malfunction

the enzyme effects on neurons are reduced in cells lacking epinephrin EFNB2 or Akt

Homo sapiens

2.1.1.1

metabolism

the effects of enzyme NNMT expression in SH-SY5Y cells, e.g. protection against the toxicity of the Complex I (CxI) inhibitors 1-methyl-4-phenylpyridinium ion and rotenone, are mediated via increased CxI activity and ATP production and the sequential activation of the epinephrin EFNB2 and Akt signalling pathways

Homo sapiens

2.1.1.1

physiological function

the enzyme NNMT expression protects against neurotoxin-mediated cell death by increasing Complex I (CxI) activity, resulting in increased ATP synthesis, mediated via protection of the NDUFS3 subunit of CxI from degradation by increased 1-methylnicotinamide production. The enzyme expression increases neurite branching and the presynaptic marker synaptophysin, synaptophysin expression is induced by the enzyme. 1-Methylnicotinamide replicates the effects of enzyme NNMT expression upon SH-SY5Y neurite branching, effects of NNMT expression on neuron morphology and differentiation, overview. Recombinant NNMT-V5 expression in SH-SY5Y cells changes cellular morphology and increases dopamine uptake and release. The effects of enzyme NNMT expression in SH-SY5Y cells, e.g. protection against the toxicity of the Complex I (CxI) inhibitors 1-methyl-4-phenylpyridinium ion and rotenone, are mediated via increased CxI activity and ATP production and the sequential activation of the epinephrin EFNB2 and Akt signalling pathways. The enzyme NNMT reduces cholinergic phenotype but does not induce terminal differentiation

Homo sapiens